ALT

3.31

2.16% 0.07

Pre-mercato: 3.33 0.02 +0.60%

Altimmune Inc (ALT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$3.24

Aprire:

$3.3

Volume 24 ore:

4.36M

Relative Volume:

0.90

Capitalizzazione di mercato:

$430.65M

Reddito:

$41,000

Utile/perdita netta:

$-88.09M

Rapporto P/E:

-3.2598

EPS:

-1.0154

Flusso di cassa netto:

$-67.55M

1 W Prestazione:

-3.22%

1M Prestazione:

-27.41%

6M Prestazione:

-15.56%

1 anno Prestazione:

-43.80%

Intervallo 1D:

$3.235

$3.385

Intervallo di 1 settimana:

$3.23

$3.53

Portata 52W:

$2.90

$7.73

Altimmune Inc Stock (ALT) Company Profile

Nome

Altimmune Inc

Settore

Healthcare (1114)

Industria

Biotechnology (623)

Telefono

(240) 654-1450

Indirizzo

910 CLOPPER ROAD, GAITHERSBURG, MD

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

ALT's Discussions on Twitter

Compare ALT vs VRTX, REGN, ALNY, ARGX, INSM

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALT Altimmune Inc	3.31	430.65M	41,000	-88.09M	-67.55M	-1.0154
VRTX Vertex Pharmaceuticals Inc	454.97	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	31.97B	606.42M	-1.28B	-997.58M	-6.403

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-18	Iniziato	Truist	Buy
2026-01-28	Iniziato	Barclays	Overweight
2025-07-10	Ripresa	Goldman	Sell
2025-02-28	Iniziato	William Blair	Mkt Perform
2025-01-08	Iniziato	Stifel	Buy
2024-11-12	Iniziato	UBS	Buy
2024-04-29	Downgrade	Guggenheim	Buy → Neutral
2024-01-24	Iniziato	Goldman	Neutral
2023-03-22	Downgrade	Goldman	Buy → Neutral
2022-12-01	Iniziato	Goldman	Buy
2021-12-29	Ripresa	Jefferies	Buy
2021-06-02	Iniziato	H.C. Wainwright	Buy
2021-02-11	Iniziato	Guggenheim	Buy
2020-12-14	Iniziato	Jefferies	Buy
2020-11-12	Reiterato	B. Riley Securities	Buy
2020-09-25	Iniziato	B. Riley FBR	Buy
2020-08-14	Iniziato	Evercore ISI	Outperform
2020-07-31	Iniziato	Piper Sandler	Overweight
2020-07-28	Iniziato	JMP Securities	Mkt Outperform
2020-02-24	Ripresa	ROTH Capital	Buy
2019-07-19	Iniziato	ROTH Capital	Buy
2017-10-09	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Altimmune Inc Borsa (ALT) Ultime notizie

Mar 25, 2026

H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases - Insider Monkey

Mar 25, 2026

Mar 24, 2026

Altimmune outlines 1,800-patient phase III MASH trial and signals cash runway into 2028 as pemvidutide advances - MSN

Mar 21, 2026

Mar 20, 2026

Growth Value: Can Altimmune Inc stock outperform in a bear marketWeekly Market Report & Consistent Income Trade Recommendations - baoquankhu1.vn

Mar 20, 2026

ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill

Mar 20, 2026

Mar 19, 2026

Viking Therapeutics: Phase 3 Obesity Data Feels Like A Coin Toss (Rating Downgrade) (VKTX) - Seeking Alpha

Mar 19, 2026

ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN

Mar 19, 2026

Mar 18, 2026

Truist initiates Altimmune stock coverage with buy rating on drug potential - Investing.com Australia

Mar 18, 2026

Altimmune (ALT) Gains Buy Rating with Promising MASH Treatment - GuruFocus

Mar 18, 2026

Altimmune (NASDAQ:ALT) Now Covered by Analysts at Truist Financial - MarketBeat

Mar 18, 2026

What is HC Wainwright's Estimate for Altimmune Q1 Earnings? - MarketBeat

Mar 18, 2026

Mar 17, 2026

Altimmune (FRA:3G0) NonCurrent Deferred Revenue : €0.14 Mil (As of Dec. 2025) - GuruFocus

Mar 17, 2026

H.C. Wainwright raises Altimmune stock price target on MASH focus By Investing.com - Investing.com Australia

Mar 17, 2026

H.C. Wainwright raises Altimmune stock price target on MASH focus - Investing.com

Mar 17, 2026

HC Wainwright Forecasts Altimmune's Q4 Earnings (NASDAQ:ALT) - MarketBeat

Mar 17, 2026

Altimmune (ALT) 2026 proxy details share and ESPP increases - Stock Titan

Mar 17, 2026

Mar 16, 2026

Altimmune (NASDAQ:ALT) Price Target Raised to $25.00 at HC Wainwright - MarketBeat

Mar 16, 2026

Altimmune (ALT) Sees Price Target Raised by HC Wainwright & Co. to $25 | ALT Stock News - GuruFocus

Mar 16, 2026

Mar 15, 2026

Does Altimmune (ALT) have the potential to rally 229.28% as Wall Street analysts expect? - MSN

Mar 15, 2026

Mar 13, 2026

3 Explosive Stocks With High Short Interest - AOL.com

Mar 13, 2026

Mar 12, 2026

Altimmune: The High Cost Of Going Solo (Rating Downgrade) (NASDAQ:ALT) - Seeking Alpha

Mar 12, 2026

Altimmune at Barclays Conference: Advancing Pemvidutide’s Potential By Investing.com - Investing.com Canada

Mar 12, 2026

Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat - MarketBeat

Mar 12, 2026

Aug Final Week: Is Altimmune Inc stock a value trap2026 Macro Impact & AI Driven Price Forecasts - baoquankhu1.vn

Mar 12, 2026

Mar 11, 2026

ALT (Altimmune) NonCurrent Deferred Revenue : $0.16 Mil (As of Dec. 2025) - GuruFocus

Mar 11, 2026

Altimmune (MEX:ALT1) NonCurrent Deferred Revenue : MXN2.88 Mil (As of Dec. 2025) - GuruFocus

Mar 11, 2026

Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up - MarketBeat

Mar 11, 2026

Altimmune at Leerink Conference: Strategic Advances in MASH Treatment By Investing.com - Investing.com Canada

Mar 11, 2026

Mar 10, 2026

Altimmune Details Pemvidutide Phase III MASH Plans, Breakthrough Status at Citizens Conference - MarketBeat

Mar 10, 2026

Altimmune at The Citizens Life Sciences Conference: Strategic Insights on Pemvidutide - Investing.com

Mar 10, 2026

ALT: Pemvidutide advances to phase 3, targeting MASH with strong efficacy and best-in-class tolerability - TradingView

Mar 10, 2026

Fireside chat set for Leerink Global Healthcare Conference, Altimmune announces - Traders Union

Mar 10, 2026

Mar 09, 2026

Altimmune Bets Big on PEMB as Phase III Nears - TipRanks

Mar 09, 2026

Altimmune to start late-stage trial for MASH candidate this year - MSN

Mar 09, 2026

Altimmune CFO Weaver buys $17,700 in shares By Investing.com - Investing.com Australia

Mar 09, 2026

Altimmune joins Citizens Life Sciences Conference for fireside chat in Miami Beach - Traders Union

Mar 09, 2026

Altimmune CEO Durso buys $70,790 in shares By Investing.com - Investing.com India

Mar 09, 2026

Altimmune CEO Durso buys $70,790 in shares - Investing.com Australia

Mar 09, 2026

Gregory Weaver Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat

Mar 09, 2026

Altimmune (NASDAQ:ALT) CEO Acquires $70,800.00 in Stock - MarketBeat

Mar 09, 2026